Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC | Zendy

Tomasz Kloskowski | Zendy; Natalia Gurtowska | Zendy; Joanna Olkowska | Zendy; Jakub Marcin Nowak | Zendy; Jan Adamowicz | Zendy; J. Tworkiewicz | Zendy; Robert Dębski | Zendy; Alina Grzanka | Zendy; Tomasz Drewa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC

Author(s) -

Tomasz Kloskowski,

Natalia Gurtowska,

Joanna Olkowska,

Jakub Marcin Nowak,

Jan Adamowicz,

J. Tworkiewicz,

Robert Dębski,

Alina Grzanka,

Tomasz Drewa

Publication year - 2012

Publication title -

international journal of oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.405

H-Index - 122

ISSN - 1019-6439

DOI - 10.3892/ijo.2012.1653

Subject(s) - cell cycle , topoisomerase , a549 cell , cell culture , biology , flow cytometry , cell , cancer research , cell growth , apoptosis , lung cancer , microbiology and biotechnology , oncology , medicine , biochemistry , in vitro , genetics

Lung cancer is one of the most common tumors and its treatment is stillinefficient. In our previous work we proved that ciprofloxacin has a differentinfluence on five cancer cell lines. Here, we aimed to compare the biologicaleffect of ciprofloxacin on cell lines representing different responses after treatment,thus A549 was chosen as a sensitive model, C6 and B16 as highly resistant. Threedifferent cell lines were analyzed (A549, B16 and C6). The characterization ofcontinuous cell growth was analyzed with the Real-Time Cell Analyzer (RTCA)-DPsystem. Cytoskeletal changes were demonstrated using immunofluorescence. The cellcycle was analyzed using flow cytometry. Ciprofloxacin was cytostatic only againstthe A549 cell line. In the case of other tested cell lines a cytostatic effectwas not observed. Cytoskeletal analysis confirms the results obtained with RTCA-DP.A549 cells were inhibited in the G2/M phase suggesting a mechanism related totopoisomerase II inhibition. The biological effects of ciprofloxacin support thehypothesis that this drug can serve as an adjuvant treatment for lung cancer,due to its properties enabling topoisomerase II inhibition.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research